Skip to main content

Table 4 Additive interactions between rs7747752 and low L-carnitine and choline for gestational diabetes mellitus

From: Interactions of CDKAL1 rs7747752 polymorphism and serum levels of L-carnitine and choline are related to increased risk of gestational diabetes mellitus

SNP

Metabolites

Multivariable model 1

Multivariable model 2

OR/estimate

P

OR/estimate

P

(95% CI)

(95% CI)

Additive interaction between rs7747752 genotypes CG (vs. GG) and low L-carnitine and cholinea

 rs7747752

L-carnitine (in nmol/mL)

   

  GG

>150

1.00

-

1.00

-

  GG

≤150

6.23 (2.89–13.5)

<0.001

4.70 (2.01–11.0)

<0.001

  CG

>150

1.23 (0.52–2.92)

0.636

1.34 (0.53–3.38)

0.541

  CG

≤150

16.1 (6.26–41.3)

<0.001

11.4 (3.98–32.9)

<0.001

  RERI

 

9.62 (−3.49 to 22.7)

 

6.40 (−3.82 to 16.6)

 

  AP

 

0.60 (0.25–0.94)

 

0.56 (0.15–0.97)

 

  SI

 

2.76 (1.07–7.16)

 

2.59 (0.88–7.62)

 

 rs7747752

Choline (in nmol/mL)

   

  GG

>110

1.00

-

1.00

-

  GG

≤110

5.07 (2.33–11.1)

<0.001

3.28 (1.27–8.49)

0.014

  CG

>110

2.03 (1.01–4.07)

0.047

2.02 (0.86–4.73)

0.105

  CG

≤110

9.01 (3.87–21.0)

<0.001

4.82 (1.79–13.0)

0.002

  RERI

 

2.91 (−3.48 to 9.31)

 

0.52 (−3.70 to 4.73)

 

  AP

 

0.32 (−0.20 to 0.84)

 

0.11 (−0.71 to 0.92)

 

  SI

 

1.57 (0.65–3.82)

 

1.16 (0.36–3.73)

 

Additive interaction between rs7747752 genotypes CC (vs. GG) and low L-carnitine and cholineb

 rs7747752

L-carnitine (in nmol/mL)

   

  GG

>150

1.00

-

1.00

-

  GG

≤150

9.57 (4.65–19.7)

<0.001

6.14 (2.61–14.4)

0.034

  CC

>150

3.55 (1.41–8.94)

0.005

3.43 (1.26–9.35)

0.034

  CC

≤150

21.7 (6.78–69.3)

<0.001

19.6 (5.65–68.1)

<0.001

  RERI

 

9.55 (−13.0 to 32.1)

 

11.1 (−10.9 to 33.0)

 

  AP

 

0.44 (−0.14 to 1.03)

 

0.56 (0.06–1.06)

 

  SI

 

1.86 (0.62–5.60)

 

2.46 (0.73–8.35)

 

 rs7747752

Choline (in nmol/mL)

   

  GG

>110

1.00

-

1.00

-

  GG

≤110

4.65 (2.37–9.12)

<0.001

2.37 (1.07–5.28)

0.047

  CC

>110

3.18 (1.42–7.11)

0.005

2.79 (1.08–7.18)

0.037

  CC

≤110

16.0 (5.03–50.8)

<0.001

12.1 (3.22–45.6)

0.001

  RERI

 

9.14 (−7.94 to 26.2)

 

7.94 (−7.28 to 23.2)

 

  AP

 

0.57 (0.11–1.03)

 

0.66 (0.20–1.11)

 

  SI

 

2.57 (0.81–8.17)

 

3.51 (0.77–16.0)

 
  1. Multivariable model 2, adjusted for choline at ≤ 110 vs. > 110 nmol/mL and ≤ 270 vs. > 270 nmol/mL, betaine ≤ 200 nmol/mL, and L-carnitine ≤ 150 nmol/mL (except for testing of its own additive interaction), in addition to the variables listed in multivariable model 1
  2. RERI > 0, AP > 0, or SI > 1 indicates a significant additive interaction
  3. Abbreviations: SNP single nucleotide polymorphism, OR odds ratio, CI confidence interval, RERI relative excess risk due to interaction, AP attributable proportion due to interaction, SI synergy index
  4. aMultivariable model 1, adjusted for traditional risk factors, including pre-pregnancy BMI, family history of diabetes in first-degree relatives, systolic blood pressure, current smoker before pregnancy, gestational weeks at glucose challenge test, and weight gain to the time of glucose challenge test, and further adjusted rs7747752 genotype (CC vs. CG/GG)
  5. bMultivariable model 1, adjusted for traditional risk factors, including pre-pregnancy BMI, family history of diabetes in first-degree relatives, systolic blood pressure, current smoker before pregnancy, gestational weeks at glucose challenge test, and weight gain to the time of glucose challenge test, and further adjusted rs7747752 genotype (CG vs. CC/GG)
Back to article page

Genes & Nutrition

ISSN: 1865-3499

Contact us